IP Library Granted Patent US 11,274,335
Granted Patent B2
US 11,274,335 · App. 17/118,234 · Granted Mar 15, 2022

Methods for the epigenetic analysis of DNA, particularly cell-free DNA

Inventors: Patrick A. Arensdorf (Palo Alto, CA); Damek Spacek (Palo Alto, CA)
Assignee: BLUESTAR GENOMICS, INC.
C12Q1/6806C07H19/06C07H21/04C07J1/00C12Q1/6827C12Q2523/10C12Q2523/115C12Q2537/164
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,274,335
App. No.
17/118,234
Granted
Mar 15, 2022
Kind
B2
Abstract

Methods are provided for the epigenetic analysis of cell-free DNA using organic boranes to convert oxidized 5-methylcytosine residues in the cell-free DNA to dihydrouracil (DHU) residues. Cell-free DNA is contacted with an organic borane selected to successively bring about reduction, deamination, and decarboxylation of oxidized 5-methylcytosine residues such as 5-carboxylcytosine and 5-formylcytosine, resulting in DHU residues in place thereof. Following amplification, the treated cell-free DNA is sequenced, with the DHU residues read as thymine residues. Reaction mixtures, kits and additional methods are also provided, as are related methods for the epigenetic analysis of DNA, including cell-free DNA.

Claims (20)

1. A method for detecting the locations of 5mC and 5hmC residues in a cell-free DNA sample comprising fragmented, adapter-ligated template DNA, wherein the method comprises:

in a first fraction of the sample,

(a) blocking 5hmC residues with a blocking reagent to yield blocked 5hmC residues;

(b) enzymatically oxidizing 5mC residues to provide oxidized 5mC residues selected from 5caC, 5fC, and combinations thereof;

(c) converting the oxidized 5mC residues to DHU by treatment with pyridine borane, thereby providing first fraction DNA comprising blocked 5hmC residues and DHU at 5mC locations; and

(d) amplifying and sequencing the first fraction DNA to provide first fraction sequence reads in which the blocked 5hmC residues read as C and DHU reads as T; and in a second fraction of the sample,

(e) oxidizing 5hmC residues with an oxidizing reagent effective to convert 5hmC residues to oxidized 5hmC residues without modifying 5mC residues, wherein the oxidized 5hmC residues are selected from 5caC, 5fC, and combinations thereof; and

(f) converting the oxidized 5hmC residues to DHU by treatment with pyridine borane, thereby providing second fraction DNA comprising unmodified 5mC residues and DHU in place of the oxidized 5hmC residues;

(g) amplifying and sequencing the second fraction DNA to provide second fraction sequence reads in which the unmodified 5mC residues read as C and DHU reads as T; and

(h) comparing the first fraction sequence reads with the second fraction sequence reads to identify 5mC and 5hmC locations in the template DNA.

2. The method of claim 1 , wherein the blocking reagent comprises β-glucosyltransferase, such that the blocking group provided in step (a) is glucose.

3. The method of claim 1 , wherein step (b) is carried out using a TET enzyme.

4. The method of claim 3 , wherein the TET enzyme comprises TET2.

5. The method of claim 1 , wherein the oxidizing reagent in step (e) is a chemical oxidizing reagent.

6. The method of claim 5 , wherein the chemical oxidizing reagent is a perruthenate salt.

7. The method of claim 6 , wherein the perruthenate salt is potassium perruthenate.

8. The method of claim 1 , wherein the cell-free DNA comprises double-stranded DNA.

9. The method of claim 1 , wherein the cell-free DNA comprises single-stranded DNA.

10. The method of claim 1 , wherein the adapter-ligated DNA comprises adapters containing a sample identifier sequence and at least one additional molecular barcode selected from a fragment identifier sequence and a strand identifier sequence.

11. The method of claim 1 , further including appending a non-sequence-related molecular barcode to the first fraction DNA, to the second fraction DNA, or to both the first fraction DNA and the second fraction DNA, during amplification.

Assignments (2)
CHANGE OF NAME Recorded Feb 24, 2023
From: BLUESTAR GENOMICS, INC.
To: CLEARNOTE HEALTH, INC.
Reel/Frame 062857/0027 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 10, 2020
From: ARENSDORF, PATRICK A.; SPACEK, DAMEK
To: BLUESTAR GENOMICS, INC.
Reel/Frame 054610/0691 →
Continuity (3)
Continuation 16275237 · Feb 13, 2019
Provisional Application 62630798 · Feb 14, 2018
Related Publication 20210262009A1 · Aug 26, 2021
Cited By (2)
US 12,351,859 US 12,630,866